The prioritation and gap of preoperative COVID-19 vaccination in cancer surgery of the breast, head and neck, and skin: A cohort study of 367 patients in an Indonesian hospital

Anwar, Sumadi Lukman; Cahyono, Roby; Hardiyanto, Herjuna; Suwardjo, Suwardjo; Darwito, Darwito; Harahap, Wirsma Arif

doi:10.1016/j.amsu.2021.103089

Cited by 3 publications

(1 citation statement)

References 32 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A prospective study done by Anwar et al with cancer patients scheduled for elective surgeries showed that the mortality and morbidity were significantly lower in the vaccinated group when compared to the unvaccinated group [ 21 ]. A multicentric, collaborative study involving 1128 patients looking at mortality and pulmonary complications, also collaborative, demonstrated that pre-operative SARS-CoV-2 vaccination led to reduced risk of both postoperative mortality and pulmonary complications in SARS-CoV-2-positive surgical patients [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccination: Does It Alter Postoperative Mortality and Morbidity in Hip Fractures?

Jagadeesh¹,

Gnany²,

Kapadi³

et al. 2022

Cureus

View full text Add to dashboard Cite

Introduction The primary aim of our study was to evaluate the impact of coronavirus disease 2019 (COVID-19) vaccination on mortality in patients with hip fractures by comparing it to those who are unvaccinated. Our secondary objective was to compare the impact on postoperative morbidity parameters like length of hospital stay and complications. Methods A total of 619 hip fractures were divided into the 'Vaccinated group' consisting of 300 patients who had COVID-19 vaccination and the 'Unvaccinated group' consisting of 319 patients who were not vaccinated. Patient demographic variables, Nottingham hip fracture score, American Society of Anesthesiologists ( ASA ) grade, type of anaesthesia used, and Charlson Comorbidity Index were collected. Our primary outcome measures were 30- and 90-day mortality. Secondary outcome measures included postoperative complications like thromboembolic complications, cardiac, and respiratory complications, etc. Mortality among the COVID-positive patients was also compared between the groups. Results Thirty-day postoperative mortality was higher in the unvaccinated group at 13.2% than in the vaccinated group at 5.3%. A similar increase in 90-day mortality was also observed in the unvaccinated group at 24.8% when compared to 14.7% in the vaccinated group(p<0.001). Despite having a higher baseline prevalence of cardiac comorbidities, the Vaccinated group had fewer post-operative cardiac, thromboembolic, and neurological complications (p>0.05). Moreover, electrolyte imbalance and AKI were also seen in fewer patients in the vaccinated group compared to the control group (p<0.05). Furthermore, it was found that among the vaccinated patients who did have perioperative COVID-19 infection, the 30-day mortality was significantly lower (10%) compared to the control group (31.2%) (p<0.001). Similarly, 90-day mortality was significantly lower (25%) compared to the control group (43.75%) (p<0.001). Conclusion Vaccination against COVID-19 independently reduced mortality and morbidity among patients with hip fractures when compared to those who are not vaccinated. Furthermore, it decreased the risk of acquiring COVID-19, and subsequent postoperative complications. Among those who are infected with COVID-19 despite vaccination, the mortality was significantly lesser.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccination: Does It Alter Postoperative Mortality and Morbidity in Hip Fractures?

Jagadeesh¹,

Gnany²,

Kapadi³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

Thyrotoxicosis occurrence in SARS-CoV-2 infection: A case report

Anwar

Wahyono

Dwianingsih

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Impacts of COVID-19 in Breast Cancer: From Molecular Mechanism to the Treatment Approach

Stipp

Corso²,

Acco

2023

CPB

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 272 million people, resulting in 5.3 million deaths worldwide from COVID-19. Breast tumors are considered the world’s most commonly diagnosed cancer. Both breast cancer and COVID-19 share common pathogenic features, represented by inflammatory mediators and the potential of SARS-CoV-2 replication in metastatic cancer cells. This may intensify viral load in patients, thereby triggering severe COVID-19 complications. Thus, cancer patients have a high risk of developing severe COVID-19 with SARS-CoV-2 infection and a higher rate of complications and death compared with non-cancer patients. The present review discusses common mechanisms between COVID-19 and breast cancer and the particular susceptibility to COVID-19 in breast cancer patients. We describe the effects of chemotherapeutic agents that are used against this cancer, which should be considered from the perspective of susceptibility to SARS-CoV-2 infection and risk of developing severe events. We also present potential drug interactions between chemotherapies that are used to treat breast cancer and drugs that are applied for COVID-19. The drugs that were identified as having the most interactions were doxorubicin and azithromycin. Both drugs can interact with each other and with other drugs, which likely requires additional drug monitoring and changes in drug dosage and timing of administration. Further clinical and observational studies of breast cancer patients who acquire COVID-19 are needed to define the best therapeutic approach when considering the course of both diseases.

show abstract

The prioritation and gap of preoperative COVID-19 vaccination in cancer surgery of the breast, head and neck, and skin: A cohort study of 367 patients in an Indonesian hospital

Cited by 3 publications

References 32 publications

COVID-19 Vaccination: Does It Alter Postoperative Mortality and Morbidity in Hip Fractures?

COVID-19 Vaccination: Does It Alter Postoperative Mortality and Morbidity in Hip Fractures?

Thyrotoxicosis occurrence in SARS-CoV-2 infection: A case report

Impacts of COVID-19 in Breast Cancer: From Molecular Mechanism to the Treatment Approach

Contact Info

Product

Resources

About